These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23140508)

  • 1. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.
    De BP; Pagovich OE; Hicks MJ; Rosenberg JB; Moreno AY; Janda KD; Koob GF; Worgall S; Kaminsky SM; Sondhi D; Crystal RG
    Hum Gene Ther; 2013 Jan; 24(1):58-66. PubMed ID: 23140508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.
    Hicks MJ; De BP; Rosenberg JB; Davidson JT; Moreno AY; Janda KD; Wee S; Koob GF; Hackett NR; Kaminsky SM; Worgall S; Toth M; Mezey JG; Crystal RG
    Mol Ther; 2011 Mar; 19(3):612-9. PubMed ID: 21206484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus.
    Koob G; Hicks MJ; Wee S; Rosenberg JB; De BP; Kaminsky SM; Moreno A; Janda KD; Crystal RG
    CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):899-904. PubMed ID: 22229312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
    Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
    PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
    Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
    Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
    PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
    Hashimoto M; Boyer JL; Hackett NR; Wilson JM; Crystal RG
    Infect Immun; 2005 Oct; 73(10):6885-91. PubMed ID: 16177368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.
    Seregin SS; Amalfitano A
    Expert Opin Biol Ther; 2009 Dec; 9(12):1521-31. PubMed ID: 19780714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cocaine vaccine dAd5GNE protects against moderate daily and high-dose "binge" cocaine use.
    Havlicek DF; Rosenberg JB; De BP; Hicks MJ; Sondhi D; Kaminsky SM; Crystal RG
    PLoS One; 2020; 15(11):e0239780. PubMed ID: 33253224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.
    Rosenberg JB; De BP; Hicks MJ; Janda KD; Kaminsky SM; Worgall S; Crystal RG
    Hum Gene Ther; 2013 Jun; 24(6):595-603. PubMed ID: 23611296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.
    Abe S; Okuda K; Ura T; Kondo A; Yoshida A; Yoshizaki S; Mizuguchi H; Klinman D; Shimada M
    J Gene Med; 2009 Jul; 11(7):570-9. PubMed ID: 19391169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
    Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
    Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.
    Matthews QL
    Mol Pharm; 2011 Feb; 8(1):3-11. PubMed ID: 21047139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa.
    Sharma A; Krause A; Xu Y; Sung B; Wu W; Worgall S
    PLoS One; 2013; 8(2):e56996. PubMed ID: 23437292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype.
    Mack CA; Song WR; Carpenter H; Wickham TJ; Kovesdi I; Harvey BG; Magovern CJ; Isom OW; Rosengart T; Falck-Pedersen E; Hackett NR; Crystal RG; Mastrangeli A
    Hum Gene Ther; 1997 Jan; 8(1):99-109. PubMed ID: 8989999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects.
    Wee S; Hicks MJ; De BP; Rosenberg JB; Moreno AY; Kaminsky SM; Janda KD; Crystal RG; Koob GF
    Neuropsychopharmacology; 2012 Apr; 37(5):1083-91. PubMed ID: 21918504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.
    Gu L; Farrow AL; Krendelchtchikov A; Matthews QL
    J Vis Exp; 2015 May; (99):e52655. PubMed ID: 25993057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.
    Matthews QL; Yang P; Wu Q; Belousova N; Rivera AA; Stoff-Khalili MA; Waehler R; Hsu HC; Li Z; Li J; Mountz JD; Wu H; Curiel DT
    Virol J; 2008 Aug; 5():98. PubMed ID: 18718011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
    Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
    Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
    Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
    J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.